Cafepharma Today

May 16 2025 - Novo CEO to depart as obesity drugmaker’s challenges rise
Novo CEO to depart as obesity drugmaker’s challenges rise
BioMarin expands enzyme expertise with $270M Inozyme buy
Amgen could owe Regeneron more than $400M after defeat in cholesterol drug antitrust suit
Eli Lilly collaborates with Rznomics on hearing loss treatment in $1.3 billion pact
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Millennium and Seattle Genetics Present Clinical Data on ADCETRIS™ (Brentuximab Vedotin) in Pediatric Patients at EMCC Annual Meeting
Yahoo/BusinessWire
Saturday, September 24, 2011 - 12:48pm
tags:
Seattle Genetics, Millennium, Adcetris, Hodgkin's lymphoma, anaplastic large-cell lymphoma
3 Undervalued Healthcare Stocks Trading Near Highs
Seeking Alpha
Saturday, September 24, 2011 - 12:46pm
tags:
Medicis, Unitedhealth Group, Cephalon
Celgene’s Alkeran Extends Life in Eye-Cancer Patients in Study
Bloomberg
Saturday, September 24, 2011 - 12:44pm
tags:
eye cancer, Celgene, Alkeran, melphalan
Roche’s Vismodegib Meets Main Goal of Advanced Skin-Cancer Study
Bloomberg
Saturday, September 24, 2011 - 12:43pm
tags:
vismodegib, Roche, basal cell carcinoma, skin cancer
StemCells, Inc. CEO Martin McGlynn Featured on Wall Street Reporter
Yahoo/GlobeNewswire
Saturday, September 24, 2011 - 12:42pm
tags:
StemCells, HuCNS-SC, spinal cord injury
MannKind to sell senior secured discount notes
Yahoo/AP
Saturday, September 24, 2011 - 12:41pm
tags:
MannKind
CHMP Recommends Astellas Pharma Europe Ltd.'s (APEL) DIFICLIR for Approval in the EU
Yahoo/PR NewsWire
Saturday, September 24, 2011 - 12:40pm
tags:
Optimer Pharmaceuticals, Astellas, Dificlir, Clostridium Difficile, fidaxomicin
How Long Does It Take to Make a Buck at Biogen Idec?
Motley Fool
Saturday, September 24, 2011 - 12:38pm
tags:
Biogen Idec
AstraZeneca Rep Is Sued By Nexium Patients
Pharmalot
Friday, September 23, 2011 - 12:28pm
tags:
AstraZeneca, Nexium, lawsuits
Enzon Pharmaceuticals Plans to Cut Almost Half of Its Workforce
Bloomberg
Friday, September 23, 2011 - 12:11pm
tags:
Enzon, layoffs
Calif. AG won't review finding in Medicis CEO girlfriend's death
Yahoo/AP
Friday, September 23, 2011 - 12:09pm
tags:
Medicis, Jonah Shacknai
ImmunoGen advances lymphoma drug candidate
Bizjournals.com
Friday, September 23, 2011 - 12:06pm
tags:
Immunogen, IMGN529, chronic lymphocytic leukemia, non-Hodgkin's lymphoma
Celgene's Revlimid Passes EU Safety Review
TheStreet.com
Friday, September 23, 2011 - 12:03pm
tags:
Celgene, Revlimid, Europe, EU, Multiple Myeloma
J&J Recall Watch: Eprex Anemia Drug Pulled on Potency Worries
WSJ Online
Friday, September 23, 2011 - 12:01pm
tags:
Eprex, anemia, recalls, JNJ
Europe Calls for Limits on Sanofi's Multaq
Motley Fool
Friday, September 23, 2011 - 11:59am
tags:
Sanofi, Multaq, Europe, EMA
Bristol CEO says "pure pharma" strategy paying off
Reuters
Friday, September 23, 2011 - 8:58am
tags:
Bristol-Myers Squibb, Pharma CEOs, Lamberto Andreotti
PharmAthene Wins Rights to Profit From Siga Smallpox Drug
Bloomberg
Friday, September 23, 2011 - 8:56am
tags:
PharmAthene, smallpox, SIGA technologies, ST-246
Could Merck Be Hiding Weakness?
Motley Fool
Friday, September 23, 2011 - 8:55am
tags:
Merck
Bayer’s Xarelto Wins EU Drug Panel Backing for Added Use
Bloomberg
Friday, September 23, 2011 - 8:55am
tags:
Bayer, bloodthinners, Xarelto, Europe
Bristol pays $24M for early-stage biotech drugs
Yahoo/AP
Thursday, September 22, 2011 - 5:32pm
tags:
Bristol-Myers Squibb, Ambrx, Relaxin, fibroblast activation protein

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.